Navigation Links
Passing of Genmab A/S' Annual General Meeting
Date:4/23/2008

t programmes to the extent of up to 2 percent of the Company's share capital and so that the consideration for such shares shall be equal to the exercise price paid for the shares in question.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using cutting-edge antibody technology, Genmab's world class discovery, development and manufacturing teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... , Oct. 27, 2014 Janssen Biotech, ... America (CCFA) announced today the launch of ... an educational campaign designed to provide resources ... on the paired role of nutrition and appropriate ... the multimedia assets associated with this release, please ...
(Date:10/26/2014)... The report "Data Center Networking Market ... WAN Optimization Appliances]: Global Advancements, Worldwide Forecasts & ... networking market into various segments with an in-depth ... identifies the factors driving this market, various restraints ... the future roadmaps. , Browse 106 market data ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 The ... Type & by Geography - Global Trends & ... market with respect to market drivers, opportunities, and ... data tables and 27 figures spread through 217 ... - Global Trends & Forecast to 2019”., ...
(Date:10/25/2014)... 23, 2014 BioProcess International (BPI), ... the 2014 BioProcess International Awards. The awards celebrate ... responsibility and technology applications that will allow the ... a global patient base. , Winners and finalists ... a very entertaining and exciting awards dinner and ...
Breaking Biology Technology:Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 2Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 4Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 2Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 4Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 2BioProcess International Announces Winners of the 2014 BioProcess International Awards 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 5
... cause of death from roadside bombs to freeway crashes. Traumatic ... to 44, often overwhelms the body,s natural blood-clotting process. ... led by Erin Lavik, a new Case Western Reserve University ... Bertram, built synthetic platelets that show promise in halting internal ...
... Calif., Dec. 16 WaferGen Biosystems, Inc. (OTC Bulletin ... systems, today announced that it will be launching the ... profiling using its SmartChip(TM) Real-Time PCR System. The ... panel of 885 microRNAs on a single SmartChip. ...
... , LAS VEGAS, Dec. 16 Cord Blood America, Inc. (OTC ... ( http://www.cordblood-america.com ) focused on bringing the life saving potential ... internationally, said today that it has reduced its debt by a ... 2009 and total debt eliminated for the year now tops $10 ...
Cached Biology Technology:Researchers take the inside route to halt bleeding 2WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System 2WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System 3WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System 4Cord Blood America Says 2009 Debt Reduction Tops $10 Million 2Cord Blood America Says 2009 Debt Reduction Tops $10 Million 3
(Date:10/28/2014)... China have published a paper in the Proceedings ... important details about key transitions in the evolution of ... algae, mosses, ferns, trees and flowers growing deep in ... and the ornamental plants adorning our homes, all plant ... history., "Our study generated DNA sequences from a vast ...
(Date:10/28/2014)... Tea and citrus fruits and juices are associated with ... new research from the University of East Anglia (UEA). ... consume foods containing flavonols and flavanones (both subclasses of ... ovarian cancer, the fifth-leading cause of cancer death among ... habits of 171,940 women aged between 25 and 55 ...
(Date:10/27/2014)... 28, 2014 – A new randomized controlled trial (RCT) ... collagen and calcium, KoACT®, was far superior to calcium ... calcium from bones and rebuilding new bone strength. An ... http://www.ncbi.nlm.nih.gov/pubmed/25314004 , ahead of print in The Journal ... conducted by Bahram H. Arjmandi, PhD, RDN, who is ...
Breaking Biology News(10 mins):New study uses DNA sequences to look back in time at key events in plant evolution 2New study uses DNA sequences to look back in time at key events in plant evolution 3Tea and citrus products could lower ovarian cancer risk, new UEA research finds 2New RCT: KoACT® beats calcium and vitamin D for optimal bone strength 2
... , A collaboration of French and Canadian researchers have found ... into a tiny pipette provides information about the adhesion between ... is a novel approach for the study of the structural ... as embryonic development, tissue growth and cancer. A paper describing ...
... 25 A two-year, $12 million contract with the ... will jumpstart human trials of three innovative research programs ... functional tissues, announced officials of the University of Pittsburgh ... the Institute,s Second Annual Open Session, Soldiers and Sailors ...
... Calif. More than a thousand microbial genomes have been ... years to better understand their roles in tasks ranging ... suggest roughly 10,000 microbial genomes will be publicly available ... not caught up with the technological advances that have ...
Cached Biology News:Pitt gets $12 million DoD contract for regenerative medicine treatment trials 2DOE JGI produces new QC tool for microbial genomes 2DOE JGI produces new QC tool for microbial genomes 3DOE JGI produces new QC tool for microbial genomes 4
... Dunbar (1994) • This book describes ... methods for preparing samples for protein ... radiometric and bioluminescence-enhanced detection systems are ... the detection and characterization of glycoprotein ...
All serum is collected from U.S.D.A. fryers and broilers. Pricing: $15/unit for 1 - 10 units; $12/unit for 11 - 50 units...
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
Reacts with MBP from human, bovine and rat, epitope 129-138. Reacts weakly with rabbit. Does not react with guinea pig....
Biology Products: